01.06.2014 • News • Mergers & Acquisitions (M&A) • Dede Willams • GlaxoSmithKline (GSK)

GSK Invites Private Equity Bids for Older Drugs

UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter.

The move is said to be part of a reshaping of the drugmaker's portfolio, which also involves a $20 billion asset swap with Novartis that will see the Swiss company acquiring GSK's oncology activities while GSK takes Novartis' vaccines business.

GSK chief Andrew Witty said last month that Britain's biggest pharmaceuticals company could dispose of individual medicines or a broader portfolio of older established products.

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.